(0) St. Louis, MO, May 04, 2021 (GLOBE NEWSWIRE) -- Curium announced today that it submitted an abbreviated new drug application for a generic version of DaTscan (Ioflupane I 123 Injection) with the U.S. Food and Drug Administration (FDA). Curium has been granted priority review by the FDA, which has set a Generic Drug User Fee Act (GDUFA) goal date in Q4 2021. Ioflupane I 123 Injection is a single-photon emission computed tomography (SPECT) brain imaging agent used to assist in the evaluation of adult patients with suspected Parkinsonian syndromes. "Curium is committed to developing generic medications for clinicians and patients at a lower cost," said Michael Patterson, Curium's North American V.P. of Marketing. "Our weekend manufacturing across our portfolio and logistical capabilities also afford the market the opportunity to scan patients starting in the beginning of the week and early in the morning."